Clinical Trials
LANCER
April 4, 2022
F2G
April 4, 2022
RLF-100
April 4, 2022
LYT-100
April 4, 2022
ACTIV-6: COVID-19 Study of Repurposed Medications
April 4, 2022
Remdesivir use in Kidney Failure
April 4, 2022
BET (ACTIV-5)
April 4, 2022
ACTIV-1 IM
April 4, 2022
Novavax
April 4, 2022
RECOVER: Post Acute Sequelae of SARS-COV2 (PASC)
January 25, 2022
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without COVID-19 infection and at varying stages before and after infection. Individuals with and without COVID-19 infection and with or without post-acute sequelae of COVID-19 infection (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. PASC symptoms include anxiety, depression, and other psychiatric disorders, sleep disorders, “brain fog”, gastrointestinal disorders, and disorders associated with the heart, lungs, kidneys, and liver.